A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06882961 In Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
At a glance
- Drugs PF-06882961 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 30 Mar 2018 Status changed from recruiting to completed.
- 05 Mar 2018 Planned End Date changed from 21 Feb 2018 to 14 Mar 2018.
- 23 Jan 2018 Planned End Date changed from 19 Jan 2018 to 21 Feb 2018.